Key result
Bivalirudin was safely used for anticoagulation during percutaneous coronary intervention in a patient with chronic lymphocytic leukemia and thrombocytopenia, with no reported complications.
Why the study?
Does bivalirudin provide safe anticoagulation in a patient with chronic lymphocytic leukemia and thrombocytopenia undergoing PCI?
Case Report (n=1)
Does bivalirudin provide safe anticoagulation in a patient with chronic lymphocytic leukemia and thrombocytopenia undergoing PCI?
Bivalirudin may be a safe anticoagulation option during PCI for patients with concomitant chronic lymphocytic leukemia and thrombocytopenia who are at increased risk of bleeding.
May support bivalirudin consideration in high-bleeding-risk PCI with CLL and thrombocytopenia; hypothesis-generating and requires prospective validation.
A patient with chronic lymphocytic leukemia and thrombocytopenia who underwent percutaneous coronary intervention (PCI) and stenting is presented. Patients with these concomitant diseases who require invasive cardiac procedures are at increased risk for ischemic and bleeding complications and the choice of anticoagulation in these patients is critical. In the present case, anticoagulation was achieved with the direct thrombin inhibitor bivalirudin. No complications were reported, and the patient tolerated the procedure well. This case suggests that bivalirudin may be safely used in patients who are at an increased risk of bleeding undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Merrill Krolick (2006) conducted a case report in Chronic lymphocytic leukemia and thrombocytopenia requiring PCI (n=1). Bivalirudin was evaluated on Ischemic and bleeding complications. Bivalirudin was safely used for anticoagulation during percutaneous coronary intervention in a patient with chronic lymphocytic leukemia and thrombocytopenia, with no reported complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: